Ken Griffin's position in Sarepta Therapeutics is currently worth $175 Million. That's 0.17% of their equity portfolio (123rd largest holding). The investor owns 1.49% of the outstanding Sarepta Therapeutics stock. The first Sarepta Therapeutics trade was made in Q2 2013. Since then Ken Griffin bought shares 53 more times and sold shares on 44 occasions. The stake costed the investor $89.4 Million, netting the investor a gain of 96% so far.